Commentary on “Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial.” Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France.: Lancet Oncol 2013;14(2):149–58 [Epub 2013 Jan 8]

Autor: Trump, Donald L.

Publikováno v: In Urologic Oncology: Seminars and Original Investigations November 2013 31(8):1845-1845

Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.

Autor: Orlando V; Department of Oncology, Ospedale Maggiore, Trieste, Italy. Electronic address: valentina.orlando@asugi.sanita.fvg.it., Drubay D; Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France., Lavaud P; Department of cancer medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France., Faivre L; Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France., Lesaunier F; Département Médico-technique, Centre François Baclesse, Caen, France., Delva R; Institut de Cancérologie de l'Ouest, Angers, France., Gravis G; Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France., Rolland F; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France., Priou F; Department of Medical Oncology, Centre Hospitalier Départemental, La Roche-sur-Yon, France., Ferrero JM; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France., Houede N; Department of Medical Oncology, Centre Hospitalier de Nimes, Nimes, France., Mourey L; Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France., Theodore C; Department of Medical Oncology, Hôpital Foch, Paris, France., Krakowski I; Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France., Berdah JF; Department of Medical Oncology, Castelluccio Hospital, Ajaccio, France., Baciuchka M; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France., Laguerre B; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France., Fléchon A; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Grosse-Goupil M; Department of Medical Oncology, Hôpital Saint-André, Bordeaux, France., Cojean-Zelek I; Department of Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France., Oudard S; Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France., Labourey JL; Department of Oncology, Hôpital de Carcassonne, Carcasonne, France., Chinet-Charrot P; Department of Oncology, Centre Henri Becquerel, Rouen, France., Legouffe E; Department of Medical Oncology, Clinique Valdegour, Nîmes, France., Lagrange JL; Department of Radiation Oncology, Hopital Henri Mondor, Université Paris Est Creteil, Créteil, France., Linassier C; Department of Medical Oncology, Hôpital Bretonneau, Tours, France., Deplanque G; Department of Oncology, Lausanne University Hospital, Lausanne, Swiss., Beuzeboc P; Oncology and Supportive Care Department, Foch Hospital, Suresnes, France., Davin JL; Clinique Sainte-Catherine, Avignon, France., Martin AL; Unicancer, Paris, France., Brihoum M; Unicancer, Paris, France., Culine S; Department of Medical Oncology, Hôpital Saint-Louis, Paris, France., Teuff GL; Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France., Fizazi K; Department of cancer medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2023 Oct; Vol. 21 (5), pp. 615.e1-615.e8. Date of Electronic Publication: 2023 May 07.

Prognostic Value of the B12/CRP Index in Older Systemically Treatable Cancer Patients.

Autor: Montegut C; Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique des Hôpitaux de Marseille (AP-HM), 13009 Marseille, France.; Coordination Unit for Geriatric Oncology (UCOG), PACA West, 13009 Marseille, France., Correard F; Pharmacy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France., Nouguerède E; Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique des Hôpitaux de Marseille (AP-HM), 13009 Marseille, France.; Coordination Unit for Geriatric Oncology (UCOG), PACA West, 13009 Marseille, France., Rey D; Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique des Hôpitaux de Marseille (AP-HM), 13009 Marseille, France.; Coordination Unit for Geriatric Oncology (UCOG), PACA West, 13009 Marseille, France., Chevalier T; Oncology Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France., Meurer M; Oncology Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France., Deville JL; Oncology Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France., Baciuchka M; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13015 Marseille, France., Pradel V; Public Health Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France., Greillier L; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13015 Marseille, France.; Marseille Cancer Research Center (CRCM), National Institute of Health and Medical Research (INSERM), National Center for Scientific Research (CNRS), Aix-Marseille University, 13009 Marseille, France., Villani P; Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique des Hôpitaux de Marseille (AP-HM), 13009 Marseille, France.; Coordination Unit for Geriatric Oncology (UCOG), PACA West, 13009 Marseille, France.; Anthropology Bio-Cultural, Law and Ethics (ADES), French Blood Agency (EFS), National Center for Scientific Research (CNRS), Aix-Marseille University, 13009 Marseille, France., Couderc AL; Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique des Hôpitaux de Marseille (AP-HM), 13009 Marseille, France.; Coordination Unit for Geriatric Oncology (UCOG), PACA West, 13009 Marseille, France.; Anthropology Bio-Cultural, Law and Ethics (ADES), French Blood Agency (EFS), National Center for Scientific Research (CNRS), Aix-Marseille University, 13009 Marseille, France.

Publikováno v: Cancers [Cancers (Basel)] 2021 Dec 30; Vol. 14 (1). Date of Electronic Publication: 2021 Dec 30.

Illness representations and quality of life in French patients suffering from lung cancer.

Autor: Masson N; LPS, Aix Marseille Univ, LPS , Aix-en-Provence, France., Dany L; LPS, Aix Marseille Univ, LPS , Aix-en-Provence, France.; Service d'Oncologie Médicale, APHM-Timone , Marseille, France., Cannone P; Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, APHM-Nord , Marseille, France., Barlesi F; Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, APHM-Nord , Marseille, France.; CRO2, INSERM U911, Aix-Marseille Univ , Marseille, France., Baciuchka M; Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, APHM-Nord , Marseille, France., Tomasini P; Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, APHM-Nord , Marseille, France.

Publikováno v: Psychology, health & medicine [Psychol Health Med] 2020 Oct; Vol. 25 (9), pp. 1119-1129. Date of Electronic Publication: 2020 Feb 17.

723PD - Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients

Autor: Vicier, C., Faivre, L., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J.-M., Houede, N., Mourey, L., Theodore, C., Krakowski, I., Berdah, J.-F., Baciuchka, M., Laguerre, B., Flechon, A., Oudard, S., Habibian, M., Culine, S., Fizazi, K.

Publikováno v: In Annals of Oncology 1 October 2016 27 Supplement 6:vi246-vi246